药学SCI论文翻译

A、B周期分别纳入病例154例和180例，其中多数研究对象为女性，两周期的女性患者比例分别为98（63.64％）和119（66.11％）。两周期均未出现新生儿及婴幼儿患者，两周期患者平均年龄分别为41.9±16.1岁，和40.6±14.2岁，老年患者（年龄＞60周岁）分别占43例（27.92％）和54例（30.00％）。 两周期的临床资料比较无统计学差异( P＞0.05)  具有可比性。虽然该药物的使用与患者的体重明确的关联性，在所有病历中均详细登记了患者的体重。

The number of patients included in Group A and B were 154 and 180, respectively. The averaged ages for group A and B were 41.9±16.1 yrs and 40.6±14.2 yrs, respectively. Most of the patients were female (group A: 63.64%, group B: 66.11%). No significant difference was noted between the clinical data before the study. 

A、B两周期按照DUE标准适应症使用的患者分别有119例（77.27%）和168例（93.33%），具体适应症见表2。A、B周期有明显禁忌症而使用该药物情况分别为18例（11.69％）和12例（6.67％），主要都是因患者有药物过敏史或过敏体质而使用参麦注射液。虽然A、B两周期在适应症选择和禁忌症的使用上都没有达到预设的标准，通过χ2检验，P值均＜0.001，说明B周期比A周期在适应症选择和禁忌症的使用方面都有显著性改善。

The number of patients showed the indications of Shenmai injection were 119 (77.27%) and 168 (93.33%), respectively. The number of patients showed the contraindications (mainly due to history of allergy) were 18 and 12 in group A and B, respectively. Compared with Group A, significant improvement was noted in the patients with indications and contraindications of Shenmai injection in Group B (P<0.01).